A systems approach towards an understanding, diagnosis and personalized treatment of autism spectrum disorders

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1235-1238

  Hu, Valerie W ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

integrative genomics; peripheral tissues; phenotypes; systems disorder

Indexed keywords

ANTICONVULSIVE AGENT;

AUTISM; AUTISM DIAGNOSTIC INTERVIEW REVISED SCORE; BEHAVIOR DISORDER; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GENOTYPE; HUMAN; LANGUAGE DISABILITY; NEUROLOGIC DISEASE; PHARMACOGENOMICS; PHENOTYPE; QUANTITATIVE TRAIT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TREATMENT INDICATION;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; EPIGENESIS, GENETIC; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; SYSTEMS BIOLOGY;

EID: 80052923256     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.94     Document Type: Review

References (24)

1. Kanner L. Early infantile autism. J. Pediatr. 25, 211-217 (1944).
2. Asperger H. Die 'autistischen psychopathen' im kindesalter. Archiv für Psychiatrie Und Nervenkrankheiten 117, 76-136 (1944).
3. Clinical Manual for the Treatment of Autism. Hollander E, Anagnostou E (Eds). American Psychiatric Publishing, Inc., Washington, DC, USA (2007).
4. Lit L, Sharp FR, Bertoglio K et al. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J. DOI: 10.1038/tpj.2011.23 (2011) (Epub ahead of print).
5. Correia CT, Almeida JP, Santos PE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics 10, 418-430 (2010).
6. Owley T, Brune CW, Salt J et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 3, 1-7 (2010).
7. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12, 171-184 (2011).
8. Watanabe RM. Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics 12, 699-701 (2011).
9. Freitag CM, Staal W, Klauck SM, Duketis E, Waltes R. Genetics of autistic disorders: review and clinical implications. Eur. Child Adolesc. Psychiatry 19, 169-178 (2010).
10. Hu VW, Steinberg ME. Novel clustering of items from the Autism Diagnostic Interview-Revised to define phenotypes within autism spectrum disorders. Autism Res. 2, 67-77 (2009).
11. Wang K, Zhang H, Ma D et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 459, 528-533 (2009).
12. Hu VW, Addington A, Hyman A. Novel autism subtype-dependent genetic variants are revealed by quantitative trait and subphenotype association analyses of published GWAS data. PLoS ONE 6(4), e190676 (2011).
13. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta 403, 47-55 (2009).
14. Hu VW, Sarachana T, Kim KS et al. Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. Autism Res. 2, 78-97 (2009).
15. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J. Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genomics 7, 118 (2006).
16. Melke J, Goubran Botros H, Chaste P et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol. Psychiatry 13, 90-98 (2008). (Pubitemid 350275181)
17. Dominick KC, Davis NO, Lainhart J, Tager-Flusberg H, Folstein S. Atypical behaviors in children with autism and children with a history of language impairment. Rese. Dev. Disabil. 28, 145-162 (2007). (Pubitemid 46274158)
18. Van Kuilenburg ABP, Vreken P, Abeling NGGM et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104, 1-9 (1999). (Pubitemid 29134634)
19. Bourgeron T. The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb. Symp. Quant. Biol. 72, 645-654 (2007).
20. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 24, 3036-3051 (2010).
21. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med. 2(24), 23 (2010).
22. Talebizadeh Z, Butler MG, Theodoro MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res. 1(4), 240-250 (2008).
23. Abu-Elneel K, Liu T, Gazzaniga FS et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 9, 153-161 (2008).
24. Sarachana T, Xu M, Wu R-C, Hu VW. Sex hormones in autism: Androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS ONE 6(2), e17116 (2011).